Top 10 Blockbuster Biotech Drugs

How to Land a Deal: Partnering with Big Pharma
Join FierceBiotech and speakers from GlaxoSmithKline, Millenium Takeda and Locust Walk Par
Clinical Trial Design 2010: How-to & What's New
NEW SPEAKERS ANNOUNCED: Barbara Tardiff, Corporate Vice President of Data Sciences at Pare

Business Development Director
Buckton Scott USA Inc. - Princeton, NJ
Biochemist - II (Associate)
Makro Scientific - West Point, PA
Biologist - II (Associate)
Makro Scientific - Boston, MA
Director of Marketing, Clinical Diagnostics
The Alpine Group - Oakland, CA
VP, Research & Development BPT
Baxter Healthcare - Deerfield, IL

CHI's Alliance Management Congress
April 13-14, 2010 — Philadelphia, PA
46th DIA Annual Meeting
June 13-17, 2010 — Washington DC
DCAT Week 2010
Mar 15-18 — Waldorf-Astoria Hotel, New York City
Biologics Forum & Networking Reception
Mar 17 — Waldorf-Astoria Hotel, New York City

Related Topics >> blockbusters | biotech drugs | Biologics

FierceBiotech is the biotech industry's daily monitor, with a special focus on drug discovery and clinical trials. Keep up to speed with the latest biotechnology trends, breakthroughs and FDA approval news. Join 66,000+ biotechnology and pharma industry professionals who get FierceBiotech via daily email. Sign up today!

About | View Sample | Privacy | Mobile Edition

Enbrel - Top 10 Blockbuster Biotech Drugs

Enbrel (Etanercept)

Companies: Amgen, Wyeth, Takeda
Sales: $7.66 billion in 2008
Indications: Rheumatoid Arthritis, Juvenile Idiopathic Arthritisc, Ankylosing Spondylitis, Plaque Psoriasis

Related:
U.K. trust sues for Enbrel royalties
Amgen defends Enbrel after J&J wins trial
Study: Enbrel plus methotrexate helps RA

Next image

Most Popular Stories

Webinars

Featured Jobs

Events

Free Newsletter

Popular Topics

Whitepapers

Top 10 Blockbuster Biotech Drugs

Enbrel - Top 10 Blockbuster Biotech Drugs

THE FIERCEMARKETS NETWORK